Loading clinical trials...

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. | Clinical Trials | Clareo Health

COMPLETED

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

NCT02234089•Ferring Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).

Eligibility

Age

All ages

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC)
•Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment

Exclusion Criteria

•Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline.
•Participation in a clinical trial at baseline and during the follow-up period

Locations (1)

Investigational site (there may be other sites in this country)

Rottweil, Germany

Key Dates

Start Date

September 1, 2014

Primary Completion Date

June 30, 2019

Completion Date

June 30, 2019

Last Updated

July 5, 2019

Enrollment

461

ACTUAL participants

Conditions

Advanced Prostate Cancer

Interventions

Degarelix

DRUG

LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)

DRUG

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

NCT06335914

Advanced Prostate Cancer

View study

RECRUITING

Whole Body MRI in Oncology

NCT06895291

LymphomaAdvanced Prostate Cancer+4 more

View study

RECRUITINGPHASE2

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 5, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

Inclusion Criteria

Exclusion Criteria

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

Whole Body MRI in Oncology

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer